Skip to Main Content

Paper Details

Discovery of YK-029A, a novel mutant EGFR inhibitor targeting both T790 M and exon 20 insertion mutations, as a treatment for NSCLC.
Eur J Med Chem
3
2023

Datasets

Release 1.2